PP
CTMX icon

PDT Partners’s CytomX Therapeutics CTMX Stock Holding History

PDT Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-138,123
Closed -$369K – 993
2022
Q1 		$369K Buy
138,123
+3,000
+2% +$11.5K 0.03% 653
2021
Q4 		$585K Buy
135,123
+29,315
+28% +$172K 0.04% 488
2021
Q3 		$539K Buy
105,808
+30,064
+40% +$161K 0.04% 462
2021
Q2 		$479K Buy
75,744
+31,132
+70% +$242K 0.03% 525
2021
Q1 		$345K Sell
44,612
-39,822
-47% -$315K 0.02% 582
2020
Q4 		$553K Sell
84,434
-23,664
-22% -$169K 0.04% 434
2020
Q3 		$719K Sell
108,098
-4,421
-4% -$32.8K 0.05% 368
2020
Q2 		$937K Buy
112,519
+33,819
+43% +$314K 0.06% 294
2020
Q1 		$604K Sell
78,700
-19,457
-20% -$136K 0.05% 326
2019
Q4 		$816K Buy
98,157
+8,120
+9% +$54.8K 0.05% 321
2019
Q3 		$664K Buy
+90,037
New +$888K 0.04% 315

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PDT Partners's CTMX Position: Q2 2022 in Review

PDT Partners sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 138,123 shares — an estimated $369K sold.

PDT Partners first reported a position in CTMX in Q3 2019 and held it in 11 quarters. The position peaked at $937K in Q2 2020. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • PDT Partners reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • PDT Partners sold 138,123 CytomX Therapeutics shares in Q2 2022, an estimated $369K.
  • PDT Partners first reported a position in CytomX Therapeutics in Q3 2019 and held it in 11 quarters.
  • PDT Partners's CytomX Therapeutics position peaked at $937K in Q2 2020.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on PDT Partners's 13F filing for Q2 2022, filed 15 Aug 2022.